These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6423338)

  • 1. Diurnal variation in valproic acid clearance.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1984 Apr; 35(4):505-9. PubMed ID: 6423338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1985 Jun; 37(6):697-700. PubMed ID: 3924464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of valproic acid in man.
    Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU
    Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
    May CA; Garnett WR
    Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.
    Nitsche V; Mascher H
    Epilepsia; 1982 Apr; 23(2):153-62. PubMed ID: 6804223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of unbound clearance on binding parameters of valproic acid to serum proteins.
    Kodama Y; Tsutsumi K; Teraoka I; Fujii I; Takeyama M
    J Clin Pharmacol; 1993 Feb; 33(2):130-5. PubMed ID: 8440760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of carbamazepine on valproic acid kinetics in normal subjects.
    Bowdle TA; Levy RH; Cutler RE
    Clin Pharmacol Ther; 1979 Nov; 26(5):629-34. PubMed ID: 387328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid dosage and plasma protein binding and clearance.
    Bowdle AT; Patel IH; Levy RH; Wilensky AJ
    Clin Pharmacol Ther; 1980 Oct; 28(4):486-92. PubMed ID: 6773716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian changes of valproate kinetics depending on meal condition in humans.
    Ohdo S; Nakano S; Ogawa N
    J Clin Pharmacol; 1992 Sep; 32(9):822-6. PubMed ID: 1430301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects.
    Brunner-Ziegler S; Jilma B; Schörgenhofer C; Winkler F; Jilma-Stohlawetz P; Koppensteiner R; Quehenberger P; Seger C; Weigel G; Griesmacher A; Brunner M
    J Thromb Haemost; 2016 Feb; 14(2):316-23. PubMed ID: 26644369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronopharmacokinetic study of valproic acid in man: comparison of oral and rectal administration.
    Yoshiyama Y; Nakano S; Ogawa N
    J Clin Pharmacol; 1989 Nov; 29(11):1048-52. PubMed ID: 2513338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
    Galimberti CA; Mazzucchelli I; Arbasino C; Canevini MP; Fattore C; Perucca E
    Epilepsia; 2006 Sep; 47(9):1569-72. PubMed ID: 16981874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.
    Hall K; Otten N; Irvine-Meek J; Leroux M; Budnick D; Verma M; Seshia SS
    Clin Pharmacokinet; 1983; 8(5):447-55. PubMed ID: 6414752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the serum protein binding of valproic acid limit the hepatic elimination?
    Kodama Y; Kuranari M; Teraoka I; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):529-32. PubMed ID: 8294164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys.
    Levy RH; Lockard JS; Patel IH; Congdon WC
    J Pharm Sci; 1977 Aug; 66(8):1154-6. PubMed ID: 408478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.
    Loiseau P; Cenraud B; Levy RH; Akbaraly R; Brachet-Liermain A; Guyot M; Morselli PL
    Clin Pharmacokinet; 1982; 7(6):544-52. PubMed ID: 6819106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian variation of cyclosporine A in renal transplanted patients.
    Reyna Rodríguez C; Jung Cook H; González López EH; Nava A
    Rev Alerg Mex; 2004; 51(1):9-12. PubMed ID: 15119750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.